BMY Announces CheckMate -017, -063 Trials Evaluating Opdivo in Previously Treated Squamous NSCLC Show Sustained Survival Benefit

By: via Benzinga
Bristol-Myers Squibb Company (NYSE: BMY) today announced longer term survival and safety data from CheckMate ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.